Assembly Biosciences (ASMB) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 119.7% versus a loss of 42.4%. Over five years, ASMB leads with a -21.3% price change compared with -52.0% for STTK. Assembly Biosciences is the larger company by market cap ($454.4 million vs $454.2 million), about 1.0 times the size.
Assembly Biosciences converts more of its revenue into profit, with a net margin of -8.5% versus -4880.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | STTK |
|---|---|---|
| Share price | $22.19 | $4.46 |
| Market cap | $454.39M | $454.22M |
| 1-day change | -1.38% | -1.98% |
| YTD return | -34.75% | +22.19% |
| 1-year return | -42.36% | +119.70% |
| 5-year return | -21.31% | -51.99% |
| P/E ratio (TTM) | 29.59 | — |
| EPS (TTM) | $0.75 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.30M | $1.00M |
| Revenue growth (YoY) | +153.52% | -82.52% |
| Net income (latest FY) | $-6.12M | $-48.81M |
| Operating margin | -16.76% | -5150.80% |
| Net margin | -8.47% | -4880.90% |
| 52-week high | $39.65 | $8.33 |
| 52-week low | $19.20 | $1.93 |
| Distance from 52-week high | -44.04% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.73% | +245.29% |
| Average volume | 309.38K | 1.20M |
| Shares outstanding | 20.48M | 101.84M |
| Employees | 73 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed ASMB by 162.1 percentage points over the past year.
- Assembly Biosciences is more profitable, keeping -8.5 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
- Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs -82.52%).
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
ASMB vs STTK FAQ
Which is bigger, Assembly Biosciences or Shattuck Labs?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $454.39M compared with $454.22M for Shattuck Labs (STTK).
Which stock has performed better over the past year, ASMB or STTK?
STTK returned +119.70% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.